6-Fluoroindirubin | 667463-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-Fluoroindirubin
• 英文别名: (Z)-6'-fluoro-[2,3'-biindolinylidene]-2',3-dione；(3Z)-6-fluoro-3-(3-oxo-1H-indol-2-ylidene)-1H-indol-2-one
• CAS: 667463-69-6
• 化学式: C₁₆H₉FN₂O₂
• 分子量: 280.258
• InChiKey: MTVUDEHQJJSQQI-YPKPFQOOSA-N

物化性质

• 熔点：
  >300 °C
• 沸点：
  478.5±45.0 °C(Predicted)
• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  6-Fluoroindirubin 在 吡啶 、 盐酸羟胺 、 四甲基胍 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 (2Z,3E)-6'-fluoro-3-((2-(1-methylpiperidin-2-yl)ethoxy)imino)-[2,3'-biindolinylidene]-2'-one
  参考文献：
  名称：

  双吲哚衍生物作为抗 Tousled 样激酶的抗癌剂的设计、合成和生物学评价

  摘要：

  本研究介绍了双吲哚分子作为抗 Tousled 样激酶 (TLK) 的抗癌剂的设计、合成和表征。我们表明，由与 ( N-甲基哌啶-2-基) 乙基部分连接的靛玉红-3'-肟基团组成的化合物2在体外对 TLK1 和 TLK2 具有抑制活性，并降低下游底物抗磷酸化水平。在复制细胞中沉默功能 1 (ASF1)。化合物2的处理DNA 复制受损，S 期进程减慢，并在复制细胞中引发 DNA 损伤反应。结构优化进一步发现了六种表现出有效的 TLK 抑制活性的衍生物，并揭示了侧链含叔胺部分的重要性。此外，衍生物6、17、19和20强烈抑制三阴性乳腺癌 MDA-MB-231 细胞、非小细胞肺癌 A549 细胞和结肠直肠癌 HCT-116 细胞的生长，而正常肺成纤维细胞MRC5 和 IMR90 细胞对这些化合物的反应较低。总之，本研究将叔胺连接的靛玉红-3'-肟确定为抑制 TLK 活性的有效抗癌剂。

  DOI：

  10.1016/j.ejmech.2021.113904
• 作为产物：
  描述：

  3-fluoro-isonitrosoacetanilide 在 硫酸 、 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 3.25h， 生成 6-Fluoroindirubin
  参考文献：
  名称：

  Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

  摘要：

  Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.

  DOI：

  10.1021/jm031016d

文献信息

• Novel Synthesis of 4- or 6-Substituted Indirubin Derivatives
  作者：Aiying Zhang、Mingfeng Yu、Tian Lan、Zenglu Liu、Zhenmin Mao

  DOI：10.1080/00397910903318591

  日期：2010.9.30

  A simple and convenient route for synthesis of a series of 4- or 6-substituted indirubin derivatives by oxidation and subsequent condensation of indoxyl and isatin is described. Acidic reaction conditions are crucial to the condensation of 4-substituted derivatives, whereas for the condensation of 6-substituted derivatives, both acidic and basic conditions work well.

  描述了通过氧化和随后缩合吲哚酚和靛红来合成一系列 4-或 6-取代的靛玉红衍生物的简单方便的途径。酸性反应条件对 4-取代衍生物的缩合至关重要，而对于 6-取代衍生物的缩合，酸性和碱性条件都适用。
• Indirubin-Type Compounds, Compositions, and Methods for Their Use
  申请人：Meijer Laurent

  公开号：US20070276025A1

  公开（公告）日：2007-11-29

  Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.

  提供了包括6-溴吲哚红、5-氨基吲哚红和N-甲基吲哚红及相关吲哚红衍生物的化合物和组合物，它们可用作选择性调节糖原合酶激酶-3、周期蛋白依赖性蛋白激酶或芳香族羟基化酶的调节剂。使用本发明的化合物提供了抑制或调节细胞生长或细胞周期的方法。在其他方面，提供了治疗原虫介导疾病、阿尔茨海默病和糖尿病的化合物和方法。
• 6-Bromoindirubin-3′-oxime derivatives are highly active colistin adjuvants against <i>Klebsiella pneumoniae</i>
  作者：Haoting Li、Anne E. Mattingly、Richard D. Smith、Roberta J. Melander、Robert K. Ernst、Christian Melander

  DOI：10.1039/d2md00370h

  日期：——

  Multidrug resistant (MDR) bacterial infections have become increasingly common, leading clinicians to rely on last-resort antibiotics such as colistin.

  多重耐药（MDR）细菌感染越来越普遍，导致临床医生不得不依赖最后的抗生素，如科利斯汀。
• Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors
  作者：Jiangmin Zhu、Yuxing Cai、Min Kong、Yalin Li、Ling Zhu、Jianfei Zhang、Zhanpeng Yu、Shishu Xu、Lihong Hong、Chen Chen、Jianguang Luo、Lingyi Kong

  DOI：10.1021/acs.jmedchem.3c01890

  日期：2024.2.22

  death has great advantages in the treatment of cancers. A series of glutathione peroxidase 4 (GPX4) and cyclin-dependent kinase (CDK) dual inhibitors were designed and synthesized, given the synergistic anticancer effect of ML162 (GPX4 inhibitor) in combination with indirubin-3′-oxime (IO) (CDK inhibitor). Compound B9 exhibited the highest potential cytotoxic activity against all four cell lines and displayed

  铁死亡和其他死亡方式的共存在癌症的治疗中具有很大的优势。鉴于 ML162 （GPX4 抑制剂） 与靛玉红-3′-肟 （IO） （CDK 抑制剂） 联合使用的协同抗癌作用，设计并合成了一系列谷胱甘肽过氧化物酶 4 （GPX4） 和细胞周期蛋白依赖性激酶 （CDK） 双重抑制剂。化合物 B9 对所有四种细胞系均表现出最高的潜在细胞毒活性，并且对 GPX4 表现出优异的抑制活性 （IC50 = 542.5 ± 0.9 nM） 和对 CDK 4/6 的选择性抑制 （IC50 = 191.2 ± 8.7、68.1 ± 1.4 nM）。机制研究表明，B9 可同时诱导 MDA-MB-231 细胞和 HCT-116 细胞的铁死亡和 G1 期细胞阻滞。与 ML162 和 IO 相比，B9 在体内表现出更强的癌细胞生长抑制作用。这些结果证明，开发有效的 GPX4/CDK 双重抑制剂是一种很有前途的恶性癌症治疗策略。
• Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases
  作者：Panagiotis Polychronopoulos、Prokopios Magiatis、Alexios-Leandros Skaltsounis、Vassilios Myrianthopoulos、Emmanuel Mikros、Aldo Tarricone、Andrea Musacchio、S. Mark Roe、Laurence Pearl、Maryse Leost、Paul Greengard、Laurent Meijer

  DOI：10.1021/jm031016d

  日期：2004.2.1

  Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.